159 related articles for article (PubMed ID: 15265049)
1. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache.
Edvinsson L
Cephalalgia; 2004 Aug; 24(8):611-22. PubMed ID: 15265049
[TBL] [Abstract][Full Text] [Related]
2. CGRP-receptor antagonism in migraine treatment.
Edvinsson L; Petersen KA
CNS Neurol Disord Drug Targets; 2007 Aug; 6(4):240-6. PubMed ID: 17691979
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic target in primary headaches - blocking theCGRP receptor.
Edvinsson L
Expert Opin Ther Targets; 2003 Jun; 7(3):377-83. PubMed ID: 12783573
[TBL] [Abstract][Full Text] [Related]
4. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications.
Edvinsson L
CNS Drugs; 2001; 15(10):745-53. PubMed ID: 11602001
[TBL] [Abstract][Full Text] [Related]
5. Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288.
Knight YE; Edvinsson L; Goadsby PJ
Neuropeptides; 1999 Feb; 33(1):41-6. PubMed ID: 10657470
[TBL] [Abstract][Full Text] [Related]
6. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine.
Rudolf K; Eberlein W; Engel W; Pieper H; Entzeroth M; Hallermayer G; Doods H
J Med Chem; 2005 Sep; 48(19):5921-31. PubMed ID: 16161996
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
Salvatore CA; Hershey JC; Corcoran HA; Fay JF; Johnston VK; Moore EL; Mosser SD; Burgey CS; Paone DV; Shaw AW; Graham SL; Vacca JP; Williams TM; Koblan KS; Kane SA
J Pharmacol Exp Ther; 2008 Feb; 324(2):416-21. PubMed ID: 18039958
[TBL] [Abstract][Full Text] [Related]
8. Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists.
Edvinsson L
Expert Opin Ther Targets; 2007 Sep; 11(9):1179-88. PubMed ID: 17845144
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of novel alpha-Calcitonin Gene-Related Peptide (CGRP) receptor peptide antagonists that are selective for human CGRP receptors.
Taylor CK; Smith DD; Hulce M; Abel PW
J Pharmacol Exp Ther; 2006 Nov; 319(2):749-57. PubMed ID: 16873605
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution.
Lennerz JK; Rühle V; Ceppa EP; Neuhuber WL; Bunnett NW; Grady EF; Messlinger K
J Comp Neurol; 2008 Mar; 507(3):1277-99. PubMed ID: 18186028
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent, cyclic calcitonin gene-related peptide receptor antagonists.
Yan LZ; Johnson KW; Rothstein E; Flora D; Edwards P; Li B; Li J; Lynch R; Vaughn R; Clemens-Smith A; McCarty D; Chow C; McKnight KL; Lu J; Nisenbaum ES; Mayer JP
J Pept Sci; 2011 May; 17(5):383-6. PubMed ID: 21412957
[TBL] [Abstract][Full Text] [Related]
12. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
Bellamy JL; Cady RK; Durham PL
Headache; 2006 Jan; 46(1):24-33. PubMed ID: 16412148
[TBL] [Abstract][Full Text] [Related]
13. Basic mechanisms of migraine and its acute treatment.
Edvinsson L; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2012 Dec; 136(3):319-33. PubMed ID: 22939884
[TBL] [Abstract][Full Text] [Related]
14. Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries.
Edvinsson L; Chan KY; Eftekhari S; Nilsson E; de Vries R; Säveland H; Dirven CM; Danser AH; MaassenVanDenBrink A
Cephalalgia; 2010 Oct; 30(10):1233-40. PubMed ID: 20855369
[TBL] [Abstract][Full Text] [Related]
15. CGRP antagonists: unravelling the role of CGRP in migraine.
Doods H; Arndt K; Rudolf K; Just S
Trends Pharmacol Sci; 2007 Nov; 28(11):580-7. PubMed ID: 17963849
[TBL] [Abstract][Full Text] [Related]
16. Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine.
Moore EL; Burgey CS; Paone DV; Shaw AW; Tang YS; Kane SA; Salvatore CA
Eur J Pharmacol; 2009 Jan; 602(2-3):250-4. PubMed ID: 19084002
[TBL] [Abstract][Full Text] [Related]
17. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine.
Tepper SJ; Cleves C
Curr Opin Investig Drugs; 2009 Jul; 10(7):711-20. PubMed ID: 19579177
[TBL] [Abstract][Full Text] [Related]
18. Neuronal signal substances as biomarkers of migraine.
Edvinsson L
Headache; 2006; 46(7):1088-94. PubMed ID: 16866713
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches.
Goadsby PJ
Drugs; 2005; 65(18):2557-67. PubMed ID: 16392873
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin gene-related peptide and substance P regulate the intestinal radiation response.
Wang J; Qiu X; Kulkarni A; Hauer-Jensen M
Clin Cancer Res; 2006 Jul; 12(13):4112-8. PubMed ID: 16818712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
